极早产儿抗生素消耗量的变化——一项为期10年的人群研究
该研究纳入挪威2009-2018年所有活产极早产儿(胎龄<32周),共5296例,描述抗生素使用趋势及地区差异。总体80%患儿接受抗生素治疗,窄谱β-内酰胺类联合氨基糖苷类的使用从100 DOT/1000 PD降至40 DOT/1000 PD(P<0.001),广谱β-内酰胺类消耗量无变化(P=0.308)。各地区万古霉素、广谱β-内酰胺类和第一代头孢菌素消耗量差异大,但脓毒症归因死亡率无差异。
要点
- 80%的极早产儿接受了抗生素治疗,最常用的是窄谱β-内酰胺类联合氨基糖苷类。
- 2009至2018年,窄谱β-内酰胺类联合氨基糖苷类使用从100降至40 DOT/1000 PD(P<0.001)。
- 广谱β-内酰胺类消耗量无显著变化(P=0.308),各地区万古霉素等消耗量差异大但脓毒症归因死亡率无差异。
核心结论
- 研究期间总体抗生素消耗量下降,但广谱β-内酰胺类和万古霉素消耗量仍存在明显地区差异,且与脓毒症归因死亡率无关。
- 作者认为结果凸显需要抗生素管理策略以减少可能促进耐药发展的抗生素消耗。
研究设计与样本
- 基于人群的10年研究,纳入2009-2018年挪威所有活产极早产儿(胎龄<32周)并入住新生儿病房者,共5296例。
- 其中3646例(69%)出生胎龄28-31周,1650例(31%)出生胎龄<28周,四个卫生区域背景特征相似。
主要发现
- 总体80%的极早产儿接受了抗生素治疗,最常用为窄谱β-内酰胺类联合氨基糖苷类。
- 2009至2018年,窄谱β-内酰胺类联合氨基糖苷类使用从100 DOT/1000 PD降至40 DOT/1000 PD(P<0.001)。
- 广谱β-内酰胺类消耗量保持不变(P=0.308)。
- 万古霉素、广谱β-内酰胺类和第一代头孢菌素消耗量存在较大地区差异,但各地区脓毒症归因死亡率无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Wide variations in antibiotic use in very preterm infants have been reported across centres despite similar rates of infection. We describe 10 year trends in use of antibiotics and regional variations among very preterm infants in Norway. PATIENTS AND METHODS: All live-born very preterm infants (<32 weeks gestation) admitted to any neonatal unit in Norway during 2009-18 were included. Main outcomes were antibiotic consumption expressed as days of antibiotic therapy (DOT) per 1000 patient days (PD), regional variations in use across four health regions, rates of sepsis and sepsis-attributable mortality and trends of antibiotic use during the study period. RESULTS: We included 5296 infants: 3646 (69%) were born at 28-31 weeks and 1650 (31%) were born before 28 weeks gestation with similar background characteristics across the four health regions. Overall, 80% of the very preterm infants received antibiotic therapy. The most commonly prescribed antibiotics were the combination of narrow-spectrum β-lactams and aminoglycosides, but between 2009 and 2018 we observed a marked reduction in their use from 100 to 40 DOT per 1000 PD (P < 0.001). In contrast, consumption of broad-spectrum β-lactams remained unchanged (P = 0.308). There were large variations in consumption of vancomycin, broad-spectrum β-lactams and first-generation cephalosporins, but no differences in sepsis-attributable mortality across regions. CONCLUSIONS: The overall antibiotic consumption was reduced during the study period. Marked regional variations remained in consumption of broad-spectrum β-lactams and vancomycin, without association to sepsis-attributable mortality. Our results highlight the need for antibiotic stewardship strategies to reduce consumption of antibiotics that may enhance antibiotic resistance development.
引用
- Huncikova Z, Stensvold HJ, Øymar KAA, et al. Variation in antibiotic consumption in very preterm infants-a 10 year population-based study. J Antimicrob Chemother. 2024. PMID: 37986613. doi:10.1093/jac/dkad358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。